1. Home
  2. GNPX vs SHFS Comparison

GNPX vs SHFS Comparison

Compare GNPX & SHFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

N/A

Current Price

$2.63

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

Logo SHF Holdings Inc.

SHFS

SHF Holdings Inc.

N/A

Current Price

$15.60

Market Cap

2.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
GNPX
SHFS
Founded
2009
2015
Country
United States
United States
Employees
13
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.1M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
GNPX
SHFS
Price
$2.63
$15.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
160.2K
★ 690.0K
Earning Date
11-13-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 95.30
EPS
N/A
★ N/A
Revenue
N/A
★ $7,673,532.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.17
$0.10
52 Week High
$12.97
$7.58

Technical Indicators

Market Signals
Indicator
GNPX
SHFS
Relative Strength Index (RSI) 33.70 77.55
Support Level $1.88 $0.99
Resistance Level $3.11 $1.41
Average True Range (ATR) 0.29 0.02
MACD -0.04 0.11
Stochastic Oscillator 11.33 76.05

Price Performance

Historical Comparison
GNPX
SHFS

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About SHFS SHF Holdings Inc.

SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The company provides compliance and loan origination services to financial institutions that wish to offer business banking, private banking, and commercial banking services to clients operating in or adjacent to the state-legal cannabis industry. Its core service offerings include: Regulatory compliance consulting and technology, Cannabis-related deposit services and Lending services. The company generates revenue through fee income, investment income, and loan program income.

Share on Social Networks: